Navigation Links
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Date:10/30/2007

Overall Survival Results Do Not Achieve Statistical Significance

IRVINE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc.'s (Nasdaq: SPPI) licensee, GPC Biotech, today announced that the Phase 3 SPARC trial evaluating satraplatin for the treatment of hormone-refractory prostate cancer did not meet its primary efficacy endpoint.

"We are indeed disappointed that the overall survival data for satraplatin did not achieve statistical significance. Drug development is inherently risky and clinical studies do sometimes fail for various reasons, which is why we built Spectrum on a business model based on a diversified portfolio of several late- and early-stage drug candidates. We are not dependent on the success or failure of any one drug," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. "We will continue to aggressively develop our four late-stage drugs, ISO-Vorin(TM), which has a January 11th FDA action date; sumatriptan injection, which we will launch with PAR Pharmaceutical Companies in the second-half of 2008; EOquin(R), which is currently enrolling patients in two Phase 3 trials; and ozarelix, where we are currently working on the protocol for the pivotal registrational trial. Furthermore, we are currently planning and/or conducting studies for elsamitrucin, lucanthone, ortataxel, RenaZorb(TM), SPI-1620 and SPI-205."

About Satraplatin

In 2002, Spectrum licensed the global rights to GPC Biotech (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB). GPC Biotech is responsible for all costs associated with the development and regulatory filings of Satraplatin. GPC Biotech has license agreements with Ph
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/21/2010)... "Tonight,s historic vote marks a major milestone in the ... and provide quality, affordable health care for millions of ... leadership of President Barack Obama and Speaker ... necessary to defeat the special interests and do what ... remember those who stood with us and those who ...
(Date:3/21/2010)... WASHINGTON, March 22, 2010 NPR,s Car Talk guys, ... motor mouths, but they always put a lid on ... confirm their serious commitment to addressing the issue of ... by teaming with the University of Utah to launch ... cartalk.com/distraction . , The center, sponsored by Allstate, ...
(Date:3/21/2010)... Lifts, will now buy back used lifts from AmeriGlide or Summit, make ... , ... (Vocus) March 21, 2010 -- 4 Stair Lifts has announced ... lifts from AmeriGlide and Summit. The company will buy them back ... are working correctly before putting them on sale at discounted prices., , ...
(Date:3/21/2010)... 2010 With stomach irritation preventing almost 2 out ... reported discovery of several substances that may be among ... pain in every cup. , Their report, presented ... Chemical Society, included the counter-intuitive finding that espresso, French ... the tummy because these roasts contain a substance that ...
(Date:3/21/2010)... from Charmaine Yoest , President & CEO of Americans United for Life Action: , ... , ... ... ... "This deal to pass the largest expansion of abortion since Roe v. Wade is a tragedy for America.  We believe ...
Breaking Medicine News(10 mins):Health News:'A Monumentally Important Victory for Our Country' 2Health News:Driver safety Web site from Car Talk, U of Utah 2Health News:4 Stair Lifts Announces Used Stair Lift Buy Back Program 2Health News:Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient 2Health News:Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient 3
... Air Pollution While EPA Shirks Responsibility , , ... TODAY released their study of schools where the outside air poses ... school staff. The study identified 435 schools in "toxic hot ... what the Center for Health, Environment and Justice (CHEJ) has been ...
... WASHINGTON, Dec. 8 The independent, non-profit, ... medical records for every doctor,s office and hospital ... key elements of which were announced as part ... Address ( http://change.gov/newsroom/entry/the_key_parts_of_the_jobs_plan/ ). , ...
... December 8 - 14; Urges Immunization into December, January and ... D.C., Dec. 8 Mothers -- often the family,s primary ... their families vaccinated against influenza throughout the winter months and ... the American Lung Association as part of its Faces ...
... Traumatic Injury Protection Program Expands Benefits , ... Veterans Affairs (VA) announced some severely injured military personnel and ... Life Insurance Traumatic Injury Protection Program, known as TSGLI . ... was created to relieve some of the financial burdens on ...
... for men with a family history of the disease, researchers say ... men living with a significant other are more prone to get ... The study, published in Cancer Epidemiology, Biomarkers & Prevention ... cancer were 40 percent less likely to be screened if they ...
... 8 Screening with an ultrasound machine has ... with sickle cell disease, by identifying children who ... an eight-year period at The Children,s Hospital of ... ultrasonography (TCD), along with regular transfusions for children ...
Other Medicine News:Health News:If Your Child Says School Makes Him Sick - He Might Be Right 2Health News:eHealth Initiative Applaudes President-Elect Obama's Recognition of the Importance of Information Technology to Improve U.S. Health Care System 2Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 2Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 3Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 4Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 5Health News:VA Announces Changes to Servicemembers' Group Life Insurance 2Health News:Ultrasound Screening Helps Prevent Stroke in Children With Sickle Cell Disease 2Health News:Ultrasound Screening Helps Prevent Stroke in Children With Sickle Cell Disease 3
(Date:3/18/2010)... , March 18 Ahead of World ... Margaret Hamburg helped public and private sector partners ... of combination treatments for tuberculosis — and replace an ... for TB Drug Development, the Critical Path Institute, and ...
(Date:3/17/2010)... 17 DURECT Corporation (Nasdaq: DRRX ) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Barclays Capital Global Healthcare ... ... , , ... ...
(Date:3/17/2010)... Early Show .  New York physician Dr. Jon Turk introduced the breakthrough treatment to millions of viewers as the bridge between facial fillers and surgical facelifts.   ... ... ... ...
Breaking Medicine Technology:Global Partners Join Forces to Speed Development of New TB Drug Combinations 2Global Partners Join Forces to Speed Development of New TB Drug Combinations 3Global Partners Join Forces to Speed Development of New TB Drug Combinations 4Global Partners Join Forces to Speed Development of New TB Drug Combinations 5Global Partners Join Forces to Speed Development of New TB Drug Combinations 6DURECT to Present at the Barclays Capital Global Healthcare Conference 2DURECT to Present at the Barclays Capital Global Healthcare Conference 3'The AccuLift Phenomenon' Kicks off on CBS' The Early Show 2'The AccuLift Phenomenon' Kicks off on CBS' The Early Show 3Embryology study offers clues to birth defects 8775 1Embryology study offers clues to birth defects 8775 2Clock Ticking In Boston Archdiocese Abortion Scandal 48361 1Clock Ticking In Boston Archdiocese Abortion Scandal 48361 2Apria Healthcare Awards Technology Solutions Contract to Perot Systems 48359 1Apria Healthcare Awards Technology Solutions Contract to Perot Systems 48359 2Apria Healthcare Awards Technology Solutions Contract to Perot Systems 48359 3
... analysis from ATHENA Study showed that Multaq(R) on ... of hospital days,by 28% in patients with atrial ... New data from the,landmark ATHENA trial showed ... of hospital stays among patients with atrial,fibrillation/atrial flutter ...
... Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher ... Compared to Standard ... and MTA: CTIC) announced today that it achieved the primary,efficacy ... for patients with advanced, relapsed aggressive non-Hodgkin,s,lymphoma (NHL) based on ...
Other Medicine Technology:Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation 2Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation 3Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation 4Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation 5Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation 6Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device....
Medicine Products: